JP2002527504A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002527504A5 JP2002527504A5 JP2000577149A JP2000577149A JP2002527504A5 JP 2002527504 A5 JP2002527504 A5 JP 2002527504A5 JP 2000577149 A JP2000577149 A JP 2000577149A JP 2000577149 A JP2000577149 A JP 2000577149A JP 2002527504 A5 JP2002527504 A5 JP 2002527504A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- naphthyl
- substituted
- cycloalkyl
- substituted phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 64
- -1 2-benzoxazolyl Chemical group 0.000 description 33
- 150000001875 compounds Chemical class 0.000 description 31
- 125000000217 alkyl group Chemical group 0.000 description 23
- 125000000753 cycloalkyl group Chemical group 0.000 description 22
- 125000001624 naphthyl group Chemical group 0.000 description 22
- 229910052739 hydrogen Inorganic materials 0.000 description 19
- 239000001257 hydrogen Substances 0.000 description 19
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 18
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 18
- 150000002431 hydrogen Chemical class 0.000 description 15
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 125000001072 heteroaryl group Chemical group 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 125000003884 phenylalkyl group Chemical group 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 125000004043 oxo group Chemical group O=* 0.000 description 3
- 125000003831 tetrazolyl group Chemical group 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 208000037906 ischaemic injury Diseases 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 125000004306 triazinyl group Chemical group 0.000 description 2
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
- NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 1
- 125000001054 5 membered carbocyclic group Chemical group 0.000 description 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 description 1
- 125000001960 7 membered carbocyclic group Chemical group 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 0 CCOC1=C(*)*C(*)=C(C)C1O Chemical compound CCOC1=C(*)*C(*)=C(C)C1O 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 150000001975 deuterium Chemical group 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 125000004970 halomethyl group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 235000005772 leucine Nutrition 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002433 mononuclear leukocyte Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/177,546 US6242422B1 (en) | 1998-10-22 | 1998-10-22 | (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases |
| US09/177,546 | 1998-10-22 | ||
| PCT/US1999/024756 WO2000023421A1 (en) | 1998-10-22 | 1999-10-22 | (SUBSTITUTED)ACYL DIPEPTIDYL INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002527504A JP2002527504A (ja) | 2002-08-27 |
| JP2002527504A5 true JP2002527504A5 (enExample) | 2006-12-07 |
Family
ID=22649018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000577149A Pending JP2002527504A (ja) | 1998-10-22 | 1999-10-22 | システインプロテアーゼのＩＣＥ／ｃｅｄ−３系の置換アシルジペプチジル抑制剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6242422B1 (enExample) |
| EP (1) | EP1123272A1 (enExample) |
| JP (1) | JP2002527504A (enExample) |
| KR (1) | KR20010093779A (enExample) |
| AU (1) | AU1221500A (enExample) |
| CA (1) | CA2347792A1 (enExample) |
| HK (1) | HK1039317A1 (enExample) |
| IL (1) | IL142665A0 (enExample) |
| NO (1) | NO20011968L (enExample) |
| WO (1) | WO2000023421A1 (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6184210B1 (en) * | 1997-10-10 | 2001-02-06 | Cytovia, Inc. | Dipeptide apoptosis inhibitors and the use thereof |
| BRPI9909660B8 (pt) * | 1998-03-19 | 2021-05-25 | Vertex Pharma | compostos inibidores de caspases, composição farmacêutica e uso de ditos compostos |
| US7053056B2 (en) * | 1998-07-02 | 2006-05-30 | Idun Pharmaceuticals, Inc. | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| US7157430B2 (en) * | 1998-10-22 | 2007-01-02 | Idun Pharmaceuticals, Inc. | (Substituted)acyl dipeptidyl inhibitors of the ICE/CED-3 family of cysteine proteases |
| AU4213500A (en) * | 1999-04-09 | 2000-11-14 | Cytovia, Inc. | Caspase inhibitors and the use thereof |
| DK1163208T3 (da) | 1999-08-06 | 2004-08-16 | Vertex Pharma | Caspaseinhibitorer og anvendelser deraf |
| BR0013666A (pt) | 1999-08-27 | 2002-05-14 | Cytovia Inc | "alfa"-hidróxi-ácidos substituìdos inibidores de caspases e o seu uso |
| EP1923386A3 (en) | 2000-03-29 | 2008-05-28 | Vertex Pharmceuticals Incorporated | Carbamate caspase inhibitors and uses thereof |
| NZ521639A (en) | 2000-03-29 | 2004-05-28 | Vertex Pharma | Carbamate caspase inhibitors and uses thereof |
| PE20011350A1 (es) | 2000-05-19 | 2002-01-15 | Vertex Pharma | PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE) |
| US20020052323A1 (en) * | 2000-08-30 | 2002-05-02 | Jinhai Wang | Quinoline-(C=O)-(multiple amino acids)-leaving group compounds for pharmaceutical compositions and reagents |
| WO2002020465A2 (en) | 2000-09-08 | 2002-03-14 | Merck Frosst Canada & Co. | Gamma-ketoacid dipeptides as inhibitors of caspase-3 |
| US6599940B2 (en) | 2000-09-13 | 2003-07-29 | Georgetown University | Synthesis of 2-hydroxymethylglutamic acid and congeners thereof |
| DE10047486A1 (de) * | 2000-09-26 | 2002-04-11 | Bayer Ag | Phenoxyphenyl Alkansulfonate |
| FR2815541B1 (fr) * | 2000-10-24 | 2008-02-29 | Lipha | Utilisation d'inhibiteurs de l'apoptose des pericytes pour le traitement et/ou la prevention de la retinopathie diabetique |
| MXPA03009647A (es) | 2001-04-19 | 2004-01-29 | Vertex Pharma | Heterociclildicarbamidas como inhibidores de caspasa. |
| US6878743B2 (en) | 2001-09-18 | 2005-04-12 | Sunesis Pharmaceuticals, Inc. | Small molecule inhibitors of caspases |
| WO2003068242A1 (en) * | 2002-02-11 | 2003-08-21 | Vertex Pharmaceuticals Incorporated | Phospholipids as caspase inhibitor prodrugs |
| US7960398B2 (en) * | 2002-04-19 | 2011-06-14 | Vertex Pharmaceuticals Incorporated | Regulation of TNF-alpha |
| FR2839309B1 (fr) * | 2002-05-03 | 2004-07-23 | Aventis Pharma Sa | Nouveaux derives de l'acide hexahydro-pyridazine-3- carboxylique, chimiotheques les contenant, leur utilisation comme medicaments, compositions pharmaceutiques les contenant et leurs procedes de preparation |
| AU2002950217A0 (en) * | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
| AU2003279035B2 (en) * | 2002-09-25 | 2009-03-12 | University Of Rochester | Caspase inhibitors as anticancer agents |
| AU2003266559B2 (en) * | 2002-09-26 | 2008-01-24 | Eisai R&D Management Co., Ltd. | Combination drug |
| EP1583726A4 (en) * | 2002-10-09 | 2009-06-10 | Activx Biosciences Inc | EFFECT-BASED PROBES AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| PE20050159A1 (es) * | 2003-05-27 | 2005-04-19 | Vertex Pharma | Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa |
| AU2003902704A0 (en) * | 2003-05-29 | 2003-06-19 | Crc For Waste Management And Pollution Control Limited Of Unsw | Process for producing a nanoscale zero-valent metal |
| KR20050034922A (ko) * | 2003-10-10 | 2005-04-15 | 주식회사 엘지생명과학 | 2-알킬-4-옥소부타노일 그룹을 함유하는 케스페이즈저해제 및 그의 약제학적 조성물 |
| JP2007510931A (ja) * | 2003-11-10 | 2007-04-26 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｉｌ−１８をモニターするための方法 |
| WO2005117846A2 (en) * | 2004-05-27 | 2005-12-15 | Vertex Pharmaceuticals Incorporated | Ice inhibitors for the treatment of autoinflammatory diseases |
| CA2768700C (en) * | 2004-03-12 | 2014-04-29 | Vertex Pharmaceuticals Incorporated | Processes and intermediates for the preparation of aspartic acetal caspase inhibitors |
| WO2006057961A1 (en) | 2004-11-24 | 2006-06-01 | Vertex Pharmaceuticals Incorporated | 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors |
| DOP2006000008A (es) * | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| WO2006095355A1 (en) * | 2005-03-07 | 2006-09-14 | Ganga Raju Gokaraju | Novel salts of boswellic acids and selectively enriched boswellic acids and processes for the same |
| EP1902014A2 (en) | 2005-07-11 | 2008-03-26 | Wyeth | Glutamate aggrecanase inhibitors |
| ATE529430T1 (de) * | 2005-07-28 | 2011-11-15 | Vertex Pharma | Caspase-hemmer-propharmaka |
| GT200600305A (es) * | 2005-10-13 | 2007-02-26 | Métodos para preparar derivados de acido glutamico | |
| JP5473334B2 (ja) | 2005-12-23 | 2014-04-16 | ジーランド ファーマ アクティーゼルスカブ | 修飾リジン模倣化合物 |
| PE20071221A1 (es) * | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
| AU2007238805B2 (en) * | 2006-04-11 | 2012-04-05 | Arena Pharmaceuticals, Inc. | Methods of using GPR119 receptor to identify compounds useful for increasing bone mass in an individual |
| EP2027143A2 (en) | 2006-05-23 | 2009-02-25 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
| US7858663B1 (en) * | 2007-10-31 | 2010-12-28 | Pisgah Laboratories, Inc. | Physical and chemical properties of thyroid hormone organic acid addition salts |
| US20080188545A1 (en) | 2006-12-21 | 2008-08-07 | Alimardanov Asaf R | Synthesis of pyrrolidine compounds |
| EA016327B1 (ru) | 2007-02-09 | 2012-04-30 | Айрм Ллк | Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы |
| EP2108960A1 (en) | 2008-04-07 | 2009-10-14 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY |
| AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
| JP2013523819A (ja) | 2010-04-06 | 2013-06-17 | アリーナ ファーマシューティカルズ， インコーポレイテッド | Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置 |
| PH12013500547A1 (en) | 2010-09-22 | 2013-06-10 | Arena Pharm Inc | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| JP6006908B2 (ja) | 2010-11-05 | 2016-10-12 | ブランダイス ユニバーシティＢｒａｎｄｅｉｓ Ｕｎｉｖｅｒｓｉｔｙ | Ｉｃｅ阻害化合物およびその使用 |
| EA023763B1 (ru) * | 2010-11-30 | 2016-07-29 | Байер Интеллектчуал Проперти Гмбх | Производные пиримидина и их применение в качестве пестицидов |
| US20140018371A1 (en) | 2011-04-01 | 2014-01-16 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2012145603A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| US9956260B1 (en) | 2011-07-22 | 2018-05-01 | The J. David Gladstone Institutes | Treatment of HIV-1 infection and AIDS |
| WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
| GB201415598D0 (en) | 2014-09-03 | 2014-10-15 | Univ Birmingham | Elavated Itercranial Pressure Treatment |
| MX386778B (es) | 2015-03-09 | 2025-03-19 | Intekrin Therapeutics Inc | Métodos para el tratamiento de enfermedad de hígado graso no alcohólico y/o lipodistrofia. |
| EP3337791B1 (en) | 2015-08-17 | 2022-08-03 | University Health Network | Inhibitors of peptidyl arginine deiminase (pad) enzymes and uses thereof |
| CN108884045B (zh) * | 2016-05-11 | 2020-12-04 | 正大天晴药业集团股份有限公司 | Caspase抑制剂及其药物组合物、用途和治疗方法 |
| CA3058806A1 (en) | 2017-04-03 | 2018-10-11 | Coherus Biosciences Inc. | Ppar.gamma. agonist for treatment of progressive supranuclear palsy |
| WO2018202865A1 (en) | 2017-05-05 | 2018-11-08 | Zealand Pharma A/S | Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease |
| CN109748843B (zh) * | 2017-11-06 | 2022-11-11 | 正大天晴药业集团股份有限公司 | Caspase抑制剂及其药物组合物、用途和治疗方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9123326D0 (en) | 1991-11-04 | 1991-12-18 | Sandoz Ltd | Improvements in or relating to organic compounds |
| TW494094B (en) | 1993-04-29 | 2002-07-11 | Vertex Pharma | Peptide analogs as irreversible interleukin-1β protease inhibitors and pharmaceutical compositions comprising the same |
| US5462939A (en) | 1993-05-07 | 1995-10-31 | Sterling Winthrop Inc. | Peptidic ketones as interleukin-1β-converting enzyme inhibitors |
| ATE170868T1 (de) | 1993-06-04 | 1998-09-15 | Vertex Pharma | Peptid-phosphinyloxymethyl-ketonen als inhibitoren von interleukin-1 beta- konvertierenden enzymen |
| US5866545A (en) | 1993-08-13 | 1999-02-02 | Merck & Co., Inc. | Substituted ketone derivatives as inhibitors of interleukin-1β converting enzyme |
| US5417457A (en) | 1993-10-28 | 1995-05-23 | Reinhardt; William S. | Indexing/organization system |
| US5714484A (en) * | 1993-12-08 | 1998-02-03 | Prototek, Inc. | α-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors |
| US5756466A (en) | 1994-06-17 | 1998-05-26 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| GB2292149A (en) | 1994-08-09 | 1996-02-14 | Ferring Res Ltd | Peptide inhibitors of pro-interleukin-1beta converting enzyme |
| CA2215211A1 (en) | 1995-03-31 | 1996-10-03 | Takeda Chemical Industries, Ltd. | Cysteine protease inhibitor |
| EP0761680A3 (en) | 1995-09-12 | 1999-05-06 | Ono Pharmaceutical Co., Ltd. | Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity |
| US5843904A (en) | 1995-12-20 | 1998-12-01 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1βconverting enzyme |
| US5919790A (en) | 1996-10-11 | 1999-07-06 | Warner-Lambert Company | Hydroxamate inhibitors of interleukin-1β converting enzyme |
| BRPI9909660B8 (pt) | 1998-03-19 | 2021-05-25 | Vertex Pharma | compostos inibidores de caspases, composição farmacêutica e uso de ditos compostos |
| AU761138B2 (en) | 1998-06-24 | 2003-05-29 | Merck & Co., Inc. | Compositions and methods for inhibiting bone resorption |
-
1998
- 1998-10-22 US US09/177,546 patent/US6242422B1/en not_active Expired - Fee Related
-
1999
- 1999-10-22 WO PCT/US1999/024756 patent/WO2000023421A1/en not_active Ceased
- 1999-10-22 IL IL14266599A patent/IL142665A0/xx unknown
- 1999-10-22 AU AU12215/00A patent/AU1221500A/en not_active Abandoned
- 1999-10-22 HK HK02100909.8A patent/HK1039317A1/zh unknown
- 1999-10-22 KR KR1020017004971A patent/KR20010093779A/ko not_active Withdrawn
- 1999-10-22 JP JP2000577149A patent/JP2002527504A/ja active Pending
- 1999-10-22 CA CA002347792A patent/CA2347792A1/en not_active Abandoned
- 1999-10-22 EP EP99970657A patent/EP1123272A1/en not_active Withdrawn
-
2001
- 2001-04-16 US US09/836,442 patent/US20020091089A1/en not_active Abandoned
- 2001-04-20 NO NO20011968A patent/NO20011968L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002527504A5 (enExample) | ||
| JP2002519406A5 (enExample) | ||
| JP2004521107A5 (enExample) | ||
| US6242422B1 (en) | (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases | |
| CA1271596A (en) | Hypotensive peptides, their preparation and their use | |
| EP0564924B1 (en) | 2-Oxoethyl derivatives as immunosuppressants | |
| EP1695961A1 (en) | Urea derivative, process for producing the same, and use | |
| CA2478094A1 (en) | Methods of inducing terminal differentiation | |
| RU2218337C2 (ru) | Производные тиазола, способ их получения и фармацевтическая композиция на их основе | |
| PL213480B1 (pl) | Pochodna maleinomidu indolilu, sposób wytwarzania pochodnej, kompozycja zawierajaca pochodna oraz zastosowanie pochodnej | |
| KR920000788A (ko) | 폴리펩티드 화합물 및 그것의 제조방법 | |
| PL207578B1 (pl) | C-terminalny modyfikowany dipeptyd oksamylowy oraz zawierająca go kompozycja farmaceutyczna i jej zastosowanie | |
| US6576766B1 (en) | Signal transduction inhibitors, compositions containing them | |
| CA2115221A1 (en) | Aminomethylene-peptides as immunosuppressants | |
| AU742040B2 (en) | Method for preventing and treating hearing loss using sensorineurotrophic compounds | |
| EP1480999A2 (en) | (substituted)acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases | |
| KR920701202A (ko) | 헤테로 사이클릭 유도체, 그의 제조방법 및 치료사용 | |
| ES2224160T3 (es) | Agente protector para organo o tejido. | |
| JP2006510606A5 (enExample) | ||
| CA2135711A1 (en) | Cyclic amino acid derivatives | |
| JPH0226629B2 (enExample) | ||
| CA2051261A1 (en) | Cardiopulmonary bypass and organ transplant using a potassium channel activator | |
| EP0966283B1 (en) | Pharmaceutical products for curing and preventing diseases resulting from the damaging of the vascular endothelial cells | |
| ITRM970441A1 (it) | Nuovi inibitori di metalloproteinasi loro uso terapeutico e procedimento per la produzione del composto di partenza nella loro | |
| KR920000762A (ko) | 아미노산 유도체 |